Clinical Research Directory
Browse clinical research sites, groups, and studies.
Injectable Semaglutide vs Dulaglutide in Individuals at Cardiovascular Risk
Sponsor: Brigham and Women's Hospital
Summary
Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Official title: Comparative Effectiveness of Semaglutide and Dulaglutide in Patients at Low, Moderate, and High Cardiovascular Risk With Type 2 Diabetes and Overweight
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
120000
Start Date
2026-01-20
Completion Date
2026-06-01
Last Updated
2026-06-02
Healthy Volunteers
No
Interventions
Semaglutide
Initiation of injectable semaglutide described in electronic health records is used as the exposure.
Dulaglutide
Initiation of dulaglutide described in electronic health records is used as the reference.
Locations (1)
Brigham and Women's Hospital
Boston, Massachusetts, United States